DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2
Enhertu (fam-Trastuzumab deruxtecan-nxki) is a HER2-targeting ADC drug jointly developed by AstraZeneca and Daiichi Sankyo, also known as DS-8201 or T-DXd.
Like this book? You can publish your book online for free in a few
minutes!